Technical Analysis for GLYC - GlycoMimetics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical GLYC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -2.92% | |
| Stochastic Reached Oversold | Weakness | -2.92% | |
| BB Squeeze Ended | Range Expansion | -2.92% | |
| Below Lower BB | Weakness | -2.92% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2019
- Sector: Healthcare
- Industry: Biotechnology
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Biotechnology Health Pharmaceutical Industry Diseases Drug Discovery Chemotherapy Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Sickle Cell Disease Pseudomonas Hematologic Cancers Nursing Research
Biotechnology Health Pharmaceutical Industry Diseases Drug Discovery Chemotherapy Clinical Trial Acute Myeloid Leukemia Design Of Experiments Product Testing Sickle Cell Disease Pseudomonas Hematologic Cancers Nursing Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.56 |
| 52 Week Low | 2.64 |
| Average Volume | 189,576 |
| 200-Day Moving Average | 6.63 |
| 50-Day Moving Average | 4.80 |
| 20-Day Moving Average | 4.23 |
| 10-Day Moving Average | 4.11 |
| Average True Range | 0.22 |
| ADX | 38.79 |
| +DI | 8.15 |
| -DI | 39.27 |
| Chandelier Exit (Long, 3 ATRs ) | 3.97 |
| Chandelier Exit (Short, 3 ATRs ) | 4.23 |
| Upper Bollinger Band | 4.63 |
| Lower Bollinger Band | 3.82 |
| Percent B (%b) | -0.2 |
| BandWidth | 19.19 |
| MACD Line | -0.25 |
| MACD Signal Line | -0.22 |
| MACD Histogram | -0.0302 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.05 | ||||
| Resistance 3 (R3) | 4.06 | 3.94 | 3.99 | ||
| Resistance 2 (R2) | 3.94 | 3.84 | 3.94 | 3.96 | |
| Resistance 1 (R1) | 3.80 | 3.78 | 3.74 | 3.79 | 3.94 |
| Pivot Point | 3.68 | 3.68 | 3.65 | 3.68 | 3.68 |
| Support 1 (S1) | 3.54 | 3.58 | 3.48 | 3.53 | 3.38 |
| Support 2 (S2) | 3.42 | 3.52 | 3.42 | 3.36 | |
| Support 3 (S3) | 3.28 | 3.42 | 3.34 | ||
| Support 4 (S4) | 3.27 |
